---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-25-000023"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:42:53.548274+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Serina presents non-immunogenic POZ-lipid data at ACS 2025 meeting

## Summary
- Randall Moreadith, M.D., Ph.D., Chief Development Officer, presented at ACS Spring 2025 in San Diego.
- Presentation titled 'A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles'.
- In rats, POZ-lipid did not trigger IgM or IgG antibody response after repeat dosing.
- In contrast, PEG-lipid standards elicited a strong and boosted antibody response.
- Non-immunogenic POZ-lipid could enable safer LNP formulations for gene therapy and RNA medicines.

## SEC filing metadata
- accession: 0001708599-25-000023
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000023/0001708599-25-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000023/ser-20250324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-25-000023
- JSON: https://secwatch.observer/filing/0001708599-25-000023.json
- Plain text: https://secwatch.observer/filing/0001708599-25-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.